SFM
ESPR

Sphera Funds Management’s Esperion Therapeutics ESPR Stock Holding History

Sphera Funds Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-36,000
Closed -$3.33M – 143
2015
Q1 		$3.33M Buy
+36,000
New +$2.32M 0.35% 69

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's ESPR Position: Q2 2015 in Review

Sphera Funds Management sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 36,000 shares — an estimated $3.33M sold.

Sphera Funds Management first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $3.33M in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Sphera Funds Management reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Sphera Funds Management sold 36,000 Esperion Therapeutics shares in Q2 2015, an estimated $3.33M.
  • Sphera Funds Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
  • Sphera Funds Management's Esperion Therapeutics position peaked at $3.33M in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.